During the corresponding time, Nexalin Technology Inc saw a revenue deteriorated by -82.77 % year on year, sequentially revenue fell by -18.66 %. While revenue at the Nexalin Technology Inc 's corporate clients
Nexalin Technology Inc's Comment on Sales, Marketing and Customers
The company provides treatment for patients with mental health disorders such as anxiety, insomnia, and depression. Its target market includes individuals who have not responded to pharmaceutical treatments or prefer alternatives to medication and invasive neurostimulators. The company focuses on patients with anxiety disorders, including generalized anxiety disorder, social anxiety disorder, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder (PTSD), and phobias. It also addresses insomnia, a common sleep disorder with significant healthcare costs and many undiagnosed cases. The company offers a clinically proven, cost-effective, drug-free technology designed for home use and monitored by licensed healthcare providers, serving patients, physicians, insurance companies, and healthcare providers seeking safer and more affordable mental health treatment options.
By CSIMarket.com Reporter Nexalin Technology, a pioneering company in brain health solutions, has announced a significant milestone: the Brazilian Health Regulatory Agency (ANVISA) has approved the sale of its Gen-2, 15 mA neurostimulation device within Brazil. This landmark approval opens a pivotal market for the company, positioning it for substantial growth in a nation grappling with a widespread mental health crisis.Brazil, with its dynamic economic landscape, stands as the ninth largest economy globally. Despite its robust economic stature, the country faces a pressing public health challenge: over 35 million of its citizens are afflicted by mental health disorders. These conditions span a wide spectr...
Nexalin Technology Inc’s Comment on Sales, Marketing and Customers
The company provides treatment for patients with mental health disorders such as anxiety, insomnia, and depression. Its target market includes individuals who have not responded to pharmaceutical treatments or prefer alternatives to medication and invasive neurostimulators. The company focuses on patients with anxiety disorders, including generalized anxiety disorder, social anxiety disorder, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder (PTSD), and phobias. It also addresses insomnia, a common sleep disorder with significant healthcare costs and many undiagnosed cases. The company offers a clinically proven, cost-effective, drug-free technology designed for home use and monitored by licensed healthcare providers, serving patients, physicians, insurance companies, and healthcare providers seeking safer and more affordable mental health treatment options.
Sources:
Nexalin Technology Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Nexalin Technology Inc’s corporate clients.
For your research, we’ve provided 9 tables on Nexalin Technology Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
225 %